Enanta Pharmaceuticals Ratios and Metrics

Market cap in millions EUR. Fiscal year is October - September.

Millions EUR. Fiscal year is Oct - Sep.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2016 - 2020
Period Ending	Nov '25 Nov 26, 2025	Sep '25 Sep 30, 2025	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Sep '21 Sep 30, 2021	2016 - 2020
Market Capitalization	351	218	197	222	1,096	991	Upgrade
Market Cap Growth	68.18%	10.81%	-11.43%	-79.73%	10.64%	26.62%	Upgrade
Enterprise Value	362	221	155	69	825	676	Upgrade
Last Close Price	11.90	10.00	9.05	10.40	52.50	49.00	Upgrade
PS Ratio	6.31	3.92	3.25	2.97	12.48	11.83	Upgrade
PB Ratio	6.37	3.95	1.70	1.09	3.35	2.88	Upgrade
P/TBV Ratio	6.37	3.95	1.70	1.09	3.35	2.88	Upgrade
EV/Sales Ratio	6.43	3.96	2.56	0.93	9.39	8.08	Upgrade
EV/FCF Ratio	-13.20	-	-	-	-	-	Upgrade
Debt / Equity Ratio	3.11	3.11	1.76	1.03	0.08	0.02	Upgrade
Asset Turnover	0.20	0.20	0.16	0.19	0.21	0.21	Upgrade
Quick Ratio	4.03	4.03	4.99	6.52	10.00	8.43	Upgrade
Current Ratio	4.21	4.21	5.21	6.73	10.45	8.82	Upgrade
Return on Equity (ROE)	-84.63%	-84.63%	-67.16%	-49.74%	-33.78%	-18.48%	Upgrade
Return on Assets (ROA)	-16.23%	-16.23%	-18.13%	-20.47%	-19.01%	-14.81%	Upgrade
Return on Capital (ROIC)	-17.19%	-17.19%	-19.16%	-21.79%	-20.52%	-15.72%	Upgrade
Return on Capital Employed (ROCE)	-36.80%	-36.80%	-38.10%	-34.30%	-35.80%	-27.20%	Upgrade
Earnings Yield	-19.86%	-32.00%	-52.86%	-56.90%	-11.33%	-6.88%	Upgrade
FCF Yield	-7.80%	-12.57%	-44.06%	-47.71%	-8.08%	-6.16%	Upgrade
Buyback Yield / Dilution	-0.85%	-0.85%	-0.90%	-1.78%	-2.14%	-1.16%	Upgrade

Source: S&P Global Market Intelligence. Standard template. Financial Sources.